A
Alessandra Anna Prete
Researcher at Sapienza University of Rome
Publications - 33
Citations - 631
Alessandra Anna Prete is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 23 publications receiving 416 citations. Previous affiliations of Alessandra Anna Prete include Policlinico Umberto I.
Papers
More filters
Journal ArticleDOI
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo,Cristina Raimondi,M. Mancini,Salvatore Caponnetto,Angela Gradilone,Orietta Gandini,Maria Mastromartino,Gabriella Del Bene,Alessandra Anna Prete,Flavia Longo,Enrico Cortesi,Paola Gazzaniga +11 more
TL;DR: The persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape, and patients could be dichotomized into two groups based PD- L1 expression on C TCs, which suggests that the persistence ofPD-L2 negative CTCS all obtained a clinical benefit, while patients with PD-CTCs all experienced progressive disease.
Journal ArticleDOI
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Fotios Loupakis,Ilaria Depetris,Paola Biason,Rossana Intini,Alessandra Anna Prete,Francesco Leone,Pasquale Lombardi,Roberto Filippi,Andrea Spallanzani,Stefano Cascinu,Luca Reggiani Bonetti,Giulia Maddalena,Nicola Valeri,Nicola Valeri,Andrea Sottoriva,Luis Zapata,Roberta Salmaso,Giada Munari,Massimo Rugge,Angelo Paolo Dei Tos,Justin Golovato,John Zachary Sanborn,Andrew Anh Nguyen,Marta Schirripa,Vittorina Zagonel,Sara Lonardi,Matteo Fassan +26 more
TL;DR: A significant correlation between higher TMB and increased number of TILs was shown and could represent predictive biomarkers of ICI efficacy in MSI-H mCRC and should be incorporated in future trials testing checkpoint inhibitors in colorectal cancer.
Journal ArticleDOI
Immunotherapy in Gastrointestinal Cancers
Letizia Procaccio,Marta Schirripa,Matteo Fassan,Loredana Vecchione,Francesca Bergamo,Alessandra Anna Prete,Rossana Intini,Chiara Manai,Vincenzo Dadduzio,Alice Boscolo,Vittorina Zagonel,Sara Lonardi +11 more
TL;DR: It is strongly believed that immunotherapy might positively affect the natural history of a subgroup of GI cancer patients improving outcome and the overall quality of life.
Journal ArticleDOI
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
Fotios Loupakis,Rossana Intini,Chiara Cremolini,Armando Orlandi,Andrea Sartore-Bianchi,Filippo Pietrantonio,Nicoletta Pella,Andrea Spallanzani,Emanuela Dell'Aquila,Mario Scartozzi,Emmanuele De Luca,Lorenza Rimassa,Vincenzo Formica,Francesco Leone,Lorenzo Calvetti,Giuseppe Aprile,Lorenzo Antonuzzo,Federica Urbano,Hans Prenen,Francesca Negri,Samantha Di Donato,Pasquale Buonandi,Gianluca Tomasello,Antonio Avallone,Fable Zustovich,Roberto Moretto,Carlotta Antoniotti,Lisa Salvatore,Maria Alessandra Calegari,Salvatore Siena,Federica Morano,Elena Ongaro,Stefano Cascinu,Daniele Santini,Pina Ziranu,Marta Schirripa,Federica Buggin,Alessandra Anna Prete,Ilaria Depetris,Paola Biason,Sara Lonardi,Vittorina Zagonel,Matteo Fassan,Massimo Di Maio +43 more
TL;DR: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy and could be useful in clinical practice and may be adopted for proper adjustments in exploratory translational analyses.
Journal ArticleDOI
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Francesca Corti,Sara Lonardi,Rossana Intini,Massimiliano Salati,Elisabetta Fenocchio,Carmen Belli,Beatrice Borelli,Marta Brambilla,Alessandra Anna Prete,Virginia Quarà,Maria Antista,Matteo Fassan,Federica Morano,Andrea Spallanzani,Margherita Ambrosini,Giuseppe Curigliano,Filippo de Braud,Vittorina Zagonel,Giovanni Fucà,Filippo Pietrantonio +19 more
TL;DR: In this paper, the Pan-Immune-Inflammation Value (PIV) is calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count.